BACKGROUND: The definition and the behaviour of familial papillary thyroid cancer (FPTC) compared to the sporadic form (SPTC) are still debated. Some authors believe that only families with 3 or more affected members represent an actual example of familial diseases. OBJECTIVES: The objective of the study was to analyse the clinicopathological features and the outcome of sporadic and familial PTC patients also according to the number of affected members. METHODS: Among 731 patients, we identified 101 (13.8%) with familial diseases, 79 with 2 affected members (FPTC-2) and 22 with 3 or more affected members (FPTC-3) followed for a mean period of 10 years. RESULTS: FPTC patients had more frequently bilateral tumour (p = 0.007). No difference was found between the 2 groups for the other evaluated variables. At the time of the first follow-up (1-2 years after initial therapy), FPTC patients had a higher rate of persistent disease. However, at the last follow-up, the clinical outcome was not different between sporadic and familial patients. When the comparison between SPTC and FPTC was performed, according to the number of affected members, a significant trend between the 3 groups was observed for tumour diameter (p = 0.002) and bilaterality (p = 0.003), while we did not observe a significant trend for both response to initial therapy (p = 0.15) and last clinical outcome (p = 0.22). CONCLUSIONS: Our results suggest that, although the clinicopathological features of FPTC may be more aggressive, the long-term outcome is similar between FPTC and SPTC. A possible explanation is that PTC has a favourable prognosis, even when clinical presentation is more aggressive.
BACKGROUND: The definition and the behaviour of familial papillary thyroid cancer (FPTC) compared to the sporadic form (SPTC) are still debated. Some authors believe that only families with 3 or more affected members represent an actual example of familial diseases. OBJECTIVES: The objective of the study was to analyse the clinicopathological features and the outcome of sporadic and familial PTC patients also according to the number of affected members. METHODS: Among 731 patients, we identified 101 (13.8%) with familial diseases, 79 with 2 affected members (FPTC-2) and 22 with 3 or more affected members (FPTC-3) followed for a mean period of 10 years. RESULTS: FPTC patients had more frequently bilateral tumour (p = 0.007). No difference was found between the 2 groups for the other evaluated variables. At the time of the first follow-up (1-2 years after initial therapy), FPTC patients had a higher rate of persistent disease. However, at the last follow-up, the clinical outcome was not different between sporadic and familial patients. When the comparison between SPTC and FPTC was performed, according to the number of affected members, a significant trend between the 3 groups was observed for tumour diameter (p = 0.002) and bilaterality (p = 0.003), while we did not observe a significant trend for both response to initial therapy (p = 0.15) and last clinical outcome (p = 0.22). CONCLUSIONS: Our results suggest that, although the clinicopathological features of FPTC may be more aggressive, the long-term outcome is similar between FPTC and SPTC. A possible explanation is that PTC has a favourable prognosis, even when clinical presentation is more aggressive.
Authors: Young Joo Park; Hwa Young Ahn; Hoon Sung Choi; Kyung Won Kim; Do Joon Park; Bo Youn Cho Journal: Thyroid Date: 2012-01-26 Impact factor: 6.568
Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky Journal: Thyroid Date: 2016-01 Impact factor: 6.568
Authors: António E Pinto; Giovani L Silva; Rui Henrique; Francisco D Menezes; Manuel R Teixeira; Valeriano Leite; Branca M Cavaco Journal: Eur J Endocrinol Date: 2013-12-21 Impact factor: 6.664
Authors: Thomas J McDonald; Albert A Driedger; Bertha M Garcia; Stanislaus H M Van Uum; Irina Rachinsky; Vijaya Chevendra; Daniel Breadner; Richard Feinn; Stephen J Walsh; Carl D Malchoff Journal: J Oncol Date: 2011-10-25 Impact factor: 4.375
Authors: Iván A González; Douglas R Stewart; Kris Ann P Schultz; Amanda P Field; D Ashley Hill; Louis P Dehner Journal: Mod Pathol Date: 2021-10-01 Impact factor: 7.842
Authors: Luis Eduardo Barbalho de Mello; Thaise Nayane Ribeiro Carneiro; Aline Neves Araujo; Camila Xavier Alves; Pedro Alexandre Favoretto Galante; Vanessa Candiotti Buzatto; Maria das Graças de Almeida; Karina Marques Vermeulen-Serpa; Sancha Helena de Lima Vale; Fernando José de Pinto Paiva; José Brandão-Neto; Janete Maria Cerutti Journal: Endocr Connect Date: 2022-01-31 Impact factor: 3.335